Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.

Advertisements

Trancatheter Aortic Valve Implantation (TAVI)

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Trans- catheter aortic valve replacement vs

Nat. Rev. Cardiol. doi: /nrcardio

Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis Ashok.

Relation of aortic regurgitation to all-cause mortality in the transcatheter aortic valve replacement (TAVR) as-treated population of the Placement of.

From: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve ReplacementA Systematic Review and Meta-analysis Ann Intern Med. 2016;165(5):

JAMA. 2014;312(2): doi: /jama Figure Legend:

From: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve ReplacementA Systematic Review and Meta-analysis Ann Intern Med. 2016;165(5):

Nat. Rev. Cardiol. doi: /nrcardio

Longevity of transcatheter and surgical bioprosthetic aortic valves in patients with severe aortic stenosis and lower surgical risk Lars Sondergaard,

Is Open Heart Surgery Too Risky For You? Opt for a Minimally Invasive Procedure.

The Ever-Expanding Patient Pool for TAVR:

Nat. Rev. Cardiol. doi: /nrcardio

Transcatheter Aortic Valve Implantation: A Canadian Cardiovascular Society Position Statement John Webb, MD, FRCPC, Josep Rodés-Cabau, MD, FRCPC, Stephen.

Figure 10 Assessment of myocardial fibrosis

Figure 5 TAVI with a self-expanding valve in

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Pathological specimens showing the most common reasons for bioprosthetic valve failure Figure 2 | Pathological specimens showing the most common.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

PARTNER 2A Trial design: Intermediate-risk patients with aortic stenosis (STS PROM score 4-8%) were randomized to undergo either TAVR or SAVR, stratified.

Figure 8 4D magnetic resonance imaging patterns

Figure 4 Valve-in-valve implantations in degenerated surgical valves

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Figure 1 Decision tree integrating the assessment,

Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.

Figure 4 TAVI for bicuspid aortic valve disease

Figure 1 Types of surgical and transcatheter aortic valves

Figure 2 A patient with aortic stenosis and mitral regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Suggested pathway for assessment of aortic valve replacement dysfunction. Suggested pathway for assessment of aortic valve replacement dysfunction. Transthoracic.

Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients.

Nat. Rev. Cardiol. doi: /nrcardio

Transcatheter aortic valve replacement in intermediate-risk patients

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Matrix signals regulate valve cell phenotypes

Baseline Clinical Characteristics

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Box plot of hospital length of stay (in days) for the STD and TAVI groups before (blue) and after (green) the TAVI/turn-down date. Box plot of hospital.

N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels for patients undergoing surgical aortic valve replacement (SAVR) (A), patients undergoing.

Nat. Rev. Cardiol. doi: /nrcardio

Deterministic univariate sensitivity analyses (BAV, balloon aortic valvuloplasty; ICU, intensive care unit; MM, medical management; QALY, quality-adjusted.

Philippe Pibarot et al. JIMG 2015;8:

NYHA before and after at least 30–60 days after TAVI

Nat. Rev. Cardiol. doi: /nrcardio

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.116 Figure 3 Valve haemodynamics and paravalvular aortic regurgitation after TAVI Figure 3 | Valve haemodynamics and paravalvular aortic regurgitation after TAVI. a | Aortic valve (AV) areas at baseline and after transcatheter AV implantation (TAVI) or surgical AV replacement (SAVR) in the PARTNER 2 trial5, which included 2,032 patients at intermediate surgical risk. b | Paravalvular regurgitation after TAVI or SAVR in the PARTNER 2 trial5. c | AV areas and mean transvalvular gradients at baseline or after TAVI or SAVR in the SURTAVI trial6, which included 1,660 patients at intermediate surgical risk. d | Paravalvular regurgitation after TAVI or SAVR in the SURTAVI trial6. Data in panels a and b obtained from Ref. 5. Data in panels c and d obtained from Ref. 6. Puri, R. et al. (2017) Future of transcatheter aortic valve implantation — evolving clinical indications Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.116